The World Health Organisation (WHO) has issued its first global guideline on the use of GLP-1 receptor agonists for treating obesity, formally recognising obesity as a chronic, relapsing disease that requires long-term, structured care. The guideline comes at a time when over 1 billion people worldwide live with obesity, and related conditions contributed to 3.7 million deaths in 2024. Without intervention, global prevalence is projected to double by 2030, underscoring an urgent need for effective therapeutic options and scalable public health strategies.

A Global Turning Point for Obesity Care

Following the inclusion of GLP-1 therapies in the WHO Essential Medicines List (2025) for high-risk diabetes management, this new guideline expands their potential use to obesity care—offering conditional recommendations for long-term treatment in adults.

According to WHO, GLP-1 medicines may be prescribed to adults (excluding pregnant women) as part of a comprehensive obesity management protocol that includes structured behavioural interventions, healthy dietary practices, physical activity, and ongoing clinical support.

WHO Director-General Dr. Tedros Adhanom Ghebreyesus emphasised that while GLP-1 medications are not a standalone solution, they can significantly support people living with obesity in managing associated health risks. “Obesity is a chronic disease requiring lifelong care. GLP-1 therapies can help millions, but medication alone won’t solve the global crisis,” he said.

Implications for Pharma and Global Health Systems

This guideline signals a new growth phase for the anti-obesity therapeutics market, already experiencing unprecedented momentum driven by GLP-1 innovations. For pharmaceutical companies, the WHO endorsement strengthens global recognition of GLP-1 therapies as clinically effective, evidence-supported options for obesity management.

However, challenges remain. WHO highlights limited long-term data, inequitable access, manufacturing constraints, and high treatment costs as factors requiring urgent global coordination. Despite increasing global demand, GLP-1 medicines are currently projected to reach fewer than 10% of eligible individuals by 2030, creating a pressing need for accelerated production and innovation in affordability models.

Building a Multi-Level Strategy Beyond Medication

The guideline reinforces that obesity cannot be addressed through pharmacotherapy alone. WHO outlines a three-pillar strategy as the foundation for sustainable impact:

1. Healthier environments: Policies enabling access to nutritious foods, physical activity, and preventive care.
2. Protection of high-risk individuals: Early screening and targeted interventions.
3. Comprehensive, person-centred care: Lifelong, multidisciplinary support integrating medical, behavioural, and community-level interventions.

Towards Equity and System Readiness

For GLP-1 therapies to meaningfully reduce global disease burden, WHO urges governments, industry stakeholders, and health systems to collaborate on:

• Affordable pricing mechanisms, including pooled procurement and tiered pricing
• Strengthening regulatory pathways
• Ensuring supply chain expansion
• Developing clinical capacity for long-term obesity care

WHO will further work with Member States and global partners through 2026 to establish equitable prioritisation frameworks, ensuring that those with the highest clinical need receive access first.

Also read: CDSCO Panel Directs Mankind Pharma to Conduct Phase I Trial in India for Sintilimab Injection Before Moving to Phase III

A Critical Moment for Pharma Innovation

The guideline positions obesity as a central frontier for next-generation therapeutics—creating opportunities for pharma innovation, manufacturing scale-up, and new models of access in low- and middle-income countries. As global health systems prepare for wider adoption of GLP-1 therapies, the pharmaceutical industry is set to play a pivotal role in shaping the future of obesity care at the population scale.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!